

Title (en)  
MODULATORS OF SORTILIN ACTIVITY

Title (de)  
MODULATOREN VON SORTILINAKTIVITÄT

Title (fr)  
MODULATEURS DE LA ACTIVITÉ DE SORTILINE

Publication  
**EP 4079748 A1 20221026 (EN)**

Application  
**EP 21170274 A 20210423**

Priority  
EP 21170274 A 20210423

Abstract (en)  
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.

IPC 8 full level  
**C07K 5/097** (2006.01); **C07K 5/06** (2006.01); **C07K 5/062** (2006.01); **C07K 5/065** (2006.01); **C07K 5/078** (2006.01)

CPC (source: EP KR US)  
**A61P 25/28** (2017.12 - KR); **A61P 29/00** (2017.12 - KR); **A61P 35/00** (2017.12 - KR); **C07C 237/12** (2013.01 - US); **C07D 209/20** (2013.01 - US); **C07D 233/64** (2013.01 - US); **C07D 241/12** (2013.01 - US); **C07D 265/30** (2013.01 - US); **C07K 5/06026** (2013.01 - EP KR); **C07K 5/06043** (2013.01 - EP KR); **C07K 5/06078** (2013.01 - EP KR); **C07K 5/06139** (2013.01 - EP KR); **C07K 5/06147** (2013.01 - EP KR); **C07K 5/06156** (2013.01 - EP KR); **C07K 5/06191** (2013.01 - EP KR); **C07K 5/0821** (2013.01 - EP KR)

Citation (applicant)

- US 2016331746 A1 20161117 - PATEL NIKETA A [US], et al
- WO 2010132601 A1 20101118 - GILEAD SCIENCES INC [US], et al
- WO 2015131100 A1 20150903 - SCRIPPS RESEARCH INST [US]
- HUANG, MOL BIOL CELL OCT, vol. 24, no. 19, 2013, pages 3115 - 22
- PAN ET AL., MOL BIOL CELL, vol. 28, no. 12, 15 June 2017 (2017-06-15), pages 1667 - 1675
- KADDAI, V ET AL.: "Involvement of TNF- $\alpha$  in abnormal adipocyte and muscle sortilin expression in obese mice and humans", DIABETOLOGIA, vol. 52, 2009, pages 932 - 940, XP019698548
- MORTENSEN, M.B. ET AL.: "Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis", J CLIN INVEST, vol. 124, no. 12, 2014, pages 5317 - 5322
- SHI, J.KANDROR, K. V.: "Sortilin Is Essential and Sufficient for the Formation of Glut4 Storage Vesicles in 3T3-L1 Adipocytes", DEVELOPMENTAL CELL, vol. 9, 2005, pages 99 - 108
- GAO, A ET AL.: "Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases", DNA AND CELL BIOLOGY, vol. 36, no. 12, 2017, pages 1050 - 1061
- OH ET AL., CARDIOVASCULAR DIABETOLOGY, vol. 16, 2017, pages 92
- SKELDAL ET AL., J. BIOL. CHEM., vol. 287, no. 52, 21 December 2012 (2012-12-21), pages 43798 - 809
- NYKJAER, A ET AL.: "Sortilin is essential for proNGF-induced neuronal cell death", NATURE, vol. 427, no. 6977, 2004, pages 843 - 848, XP002321660, DOI: 10.1038/nature02319
- WUTS, P.G.M.GREENE, T.W.: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY AND SONS
- ANDERSEN ET AL., ACTA CRYST. D, 2017
- AFONINE ET AL., ACTA CRYST. D, 2012
- EMSLEY P ET AL., ACTA CRYST. D, 2010
- TAURIS, J. ET AL.: "Proneurotrophin-3 May Induce Sortilin-Dependent Death In Inner Ear Neurons", EUR J NEUROSCIENCE, vol. 33, no. 4, 2020, pages 622 - 31, XP055785988, DOI: 10.1111/j.1460-9568.2010.07556.x
- GOETTSCHE, C. ET AL.: "Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases", ATHEROSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 38, no. 1, 2017, pages 19 - 25
- WILLNOW, T.E. ET AL.: "Sortilins: new players in lipoprotein metabolism", CURRENT OPINION IN LIPIDOLOGY, vol. 22, no. 2, 2011, pages 79 - 85
- KJOLBY, M. ET AL.: "Sortil, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export", CELL METABOLISM, vol. 12, no. 3, 2010, pages 213 - 223
- JANSEN, P. ET AL.: "Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury", NATURE NEUROSCIENCE, vol. 10, no. 11, 2007, pages 1449 - 1457, XP002478373, DOI: 10.1038/nn2000
- TENK, H.K. ET AL.: "ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin", J NEUROSCIENCE, vol. 10, no. 11, 2005, pages 1449 - 1457
- HUANG, G ET AL.: "Insulin responsiveness of glucose transporter 4 in 3T3-L1 cells depends on the presence of sortilin", MOL BIOL CELL, vol. 24, no. 19, 2013, pages 3115 - 3122
- PAN, X ET AL.: "Sortilin and retromer mediate retrograde transport of Glut4 in 3T3-L1 adipocytes", MOL BIOL CELL, vol. 28, no. 12, 2017, pages 1667 - 1675
- OH, T.J. ET AL.: "Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus", CARDIOVASCULARDIABETOLOGY, vol. 16, no. 92, 2017
- SKELDAL, S ET AL.: "Mapping of the Interaction Site between Sortilin and the p75 Neurotrophin Receptor Reveals a Regulatory Role for the Sortilin Intracellular Domain in p75 Neurotrophin Receptor Shedding and Apoptosis", J BIOL CHEM, vol. 21, no. 287, 2012, pages 43798 - 43809
- ANDERSEN, K R ET AL.: "Introducing site-specific cysteines into nanobodies for mercury labelling allows de novo phasing of their crystal structures", ACTA CRYSTALLOGRAPHIA SECTION. D, vol. 73, no. 1, 2017, pages 804 - 813, XP055617889, DOI: 10.1107/S2059798317013171
- KABSCH, W: "XDS", ACTA CRYSTALLOGRAPHIA SECTION. D, vol. 66, no. 2, 2010, pages 125 - 132
- AFONINE, P V ET AL., ACTA CRYSTALLOGRAPHIA SECTION. D, vol. 68, no. 4, 2012, pages 352 - 367
- EMSLEY, P ET AL., ACTA CRYSTALLOGRAPHIA SECTION. D, vol. 66, no. 4, 2010, pages 486 - 501

Citation (search report)

- [AD] US 2016331746 A1 20161117 - PATEL NIKETA A [US], et al
- [A] WO 2014114779 A1 20140731 - LUNDBECK & CO AS H [DK]

Cited by

WO2024089049A1; EP4361165A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**EP 4079748 A1 20221026**; AU 2022260554 A1 20231102; AU 2022260554 A9 20231116; CA 3215848 A1 20221027;  
CN 117677627 A 20240308; EP 4326742 A1 20240228; JP 2024517678 A 20240423; KR 20240000510 A 20240102;  
US 2024217922 A1 20240704; WO 2022223805 A1 20221027

DOCDB simple family (application)

**EP 21170274 A 20210423**; AU 2022260554 A 20220422; CA 3215848 A 20220422; CN 202280030307 A 20220422;  
EP 2022060742 W 20220422; EP 22724745 A 20220422; JP 2023565327 A 20220422; KR 20237037613 A 20220422;  
US 202218556406 A 20220422